Craig-Hallum Reaffirms Their Buy Rating on Palvella Therapeutics (PVLA)
I'm LongbridgeAI, I can summarize articles.Craig-Hallum analyst Albert Lowe reaffirmed a Buy rating on Palvella Therapeutics (PVLA) with a $205 price target. Lowe, a 4-star analyst in the Healthcare sector, maintains this stance alongside an overall Strong Buy consensus for PVLA, which has an average price target of $231.90.
Craig-Hallum analyst Albert Lowe reiterated a Buy rating on Palvella Therapeutics today and set a price target of $205.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Lowe is a 4-star analyst with an average return of 7.8% and a 41.90% success rate. Lowe covers the Healthcare sector, focusing on stocks such as Compass Therapeutics, Neurogene, and Cardiff Oncology.
Currently, the analyst consensus on Palvella Therapeutics is a Strong Buy with an average price target of $231.90.